

**What Is Claimed Is:**

- 5      Claim 1.      A method for the treatment of sepsis, inflammation or infection comprising providing to a recipient a physiologically effective amount of a pharmaceutical composition comprising a molecule that targets SR-BI/CLA-1.
- Claim 2.      The method of claim 1, wherein said method provides a treatment for sepsis.
- Claim 3.      The method of claim 1, wherein said method provides a treatment for inflammation.
- 10    Claim 4.      The method of claim 1, wherein said method provides a treatment for infection.
- Claim 5.      The method of claim 1, wherein said molecule is a peptide or is a peptide composition having a peptide portion.
- 15    Claim 6.      The method of claim 5, wherein said peptide or peptide composition effects LPS-uptake or LPS-stimulated cytokine production.
- Claim 7.      The method of claim 6, wherein said molecule is a peptide that binds to an anionic amphipathic  $\alpha$ -helix of SR-BI/CLA-1.
- Claim 8.      The method of claim 7, wherein said peptide is composed solely of L-amino acid residues.
- 20    Claim 9.      The method of claim 7, wherein said peptide is composed solely of D-amino acid residues.
- 25    Claim 10.     The method of claim 5, wherein said molecule is a peptide composition and wherein said peptide portion of said peptide composition binds to an anionic amphipathic  $\alpha$ -helix of SR-BI/CLA-1.

- Claim 11. The method of claim 10, wherein said peptide portion of said peptide composition is composed solely of L-amino acid residues.
- Claim 12. The method of claim 10, wherein said peptide portion of said peptide composition is composed solely of D-amino acid residues.
- 5 Claim 13. The method of claim 1, wherein said molecule is selected from the group consisting of a cholesterol absorption inhibitor, a viral fusion inhibitor, a negatively charged lipid that binds to CLA-1 with a  $K_d$  lower than  $10^{-7}$  M; an anti-SR-BI/CLA-1 antibody, or fragment thereof that binds SR-BI/CLA-1, and a chemical substance that  
10 binds to SR-BI/CLA-1 with a  $K_d$  lower than  $10^{-7}$  M.
- Claim 14. A pharmaceutical composition for the treatment of sepsis, inflammation or infection comprising providing to a recipient a physiologically effective amount of a pharmaceutical composition comprising:  
15 (A) a molecule that targets SR-BI/CLA-1; and  
(B) an auxiliary agent, excipient, or uptake facilitating agent.
- Claim 15. The pharmaceutical composition of claim 14, wherein said physiologically effective amount is effective for providing a treatment for sepsis.
- 20 Claim 16. The pharmaceutical composition of claim 14, wherein said physiologically effective amount is effective for providing a treatment inflammation.
- Claim 17. The pharmaceutical composition of claim 14, wherein said physiologically effective amount is effective for providing a  
25 treatment infection.
- Claim 18. The pharmaceutical composition of claim 14, wherein said molecule is a peptide or is a peptide composition having a peptide portion.

- Claim 19. The pharmaceutical composition of claim 18, wherein said peptide or peptide composition effects LPS-uptake or LPS-stimulated cytokine production.
- 5 Claim 20. The pharmaceutical composition of claim 18, wherein said molecule is a peptide that binds to an anionic amphipathic  $\alpha$ -helix of SR-BI/CLA-1.
- Claim 21. The pharmaceutical composition of claim 19, wherein said peptide is composed solely of L-amino acid residues.
- 10 Claim 22. The pharmaceutical composition of claim 19, wherein said peptide is composed solely of D-amino acid residues.
- Claim 23. The pharmaceutical composition of claim 18, wherein said molecule is a peptide composition and wherein said peptide portion of said peptide composition binds to an anionic amphipathic  $\alpha$ -helix of SR-BI/CLA-1.
- 15 Claim 24. The pharmaceutical composition of claim 23, wherein said peptide portion of said peptide composition is composed solely of L-amino acid residues.
- Claim 25. The pharmaceutical composition of claim 23, wherein said peptide portion of said peptide composition is composed solely of D-amino acid residues.
- 20 Claim 26. The pharmaceutical composition of claim 14, wherein said molecule is selected from the group consisting of a cholesterol absorption inhibitor, a viral fusion inhibitor, a negatively charged lipid that binds to CLA-1 with a  $K_d$  lower than  $10^{-7}$  M; an anti-SR-BI/CLA-1 antibody, of fragment thereof that binds SR-BI/CLA-1, and a chemical substance that binds to SR-BI/CLA-1 with a  $K_d$  lower than  $10^{-7}$  M.
- 25